disclaimer - cancure · 2015. 11. 5. · cv9202 lung preclinical licence us$45m upfront us$556m...

Cancure Limited Series A Capital Raise – November 2015

Cancure Limited

Investor Presentation

Series A Capital Raise

01 November 2015


DISCLAIMER

Cancure and its officers, employees, consultants and advisors:

• Do not make any guarantee, representation or warranty, either expressed or implied concerning the accuracy, completeness or

reliability of the information contained in this Investor Presentation or accept any responsibility for errors or omissions in any

information contained in this Investor Presentation or the future performance of Cancure; and

• Disclaim and exclude all liability for losses including consequential loss, claims, damages and costs of whatever nature arising in

any way out of or in connection with the provision of the Investor Presentation (or any accompanying or other information) and

any inaccuracy or incompleteness or reliance by any person on any of it.

Specifically, Cancure does not warrant or represent that the information contained in this Investor Presentation has been audited, except

where specifically stated otherwise and where required by law. The Investor Presentation is intended for review in conjunction with Cancure’s

complete Information Memorandum. Recipients should seek appropriate professional advice in reviewing the Investor Presentation and the

Information Memorandum, and in evaluating the suitability of the investment.

The Investor Presentation may include forward-looking statements, which reflect various assumptions. Those assumptions may or may not

prove to be correct. Actual results may be materially affected by changes in economic and other circumstances. The reliance that recipients

place upon such information is a matter for their own commercial judgement.

All warranties, conditions, liabilities or representations in relation to information or advice contained in this Investor Presentation are expressly

negated and excluded to the maximum extent permitted by law. The recipient agrees, to the fullest extent permitted by law that he/she shall not

seek to sue or hold Cancure or its officers, employees, consultants and advisors liable in any respect by reason of provision of the Investor

Presentation.


CONTENTS (* indicates content redacted for website publication)

Investment Highlights

Summary of SERIES A Offer *

Oncology Drug Market

Market Positioning of Cancure’s Pipeline

Lead Product Candidates

CNC118, CNC225, CNC332

Board & Management

Use of Funds *

Value Realisation & Growth Projections *

Offer Timetable *

Contact Details

Appendices

Development Plan & Financials *

Ownership Interests & Corporate Structure *

High magnification image of a cancer-fighting human T cell (US NIH).


• Cancure Limited is a clinical-stage cancer drug development company.

• Over A$15 million of investment and R&D funding in the past decade.

• Three drug candidates in the pipeline, each with billion dollar potential.

• Pilot Phase 1 human clinical trial completed for therapeutic cancer vaccine.

• Ideally positioned in the immuno-oncology revolution.

• Robust roadmap to commercialisation.

• Experienced scientific experts and business team.

• Dr. Ian Nisbet (CSL, Millennium) appointed CEO.

• Opportunity for significant value uplift in 3-5 year time horizon.

• IP protected by worldwide patents covering major markets.

• Investment leveraged by up to 45% with Australian R&D tax incentive.

INVESTMENT HIGHLIGHTS


ONCOLOGY DRUG MARKET

• Oncology is the top selling drug category in developed markets at ~ US$100 billion per annum.

• Average cost per month for a branded oncology drug in the United States is ~ US$10,000.

• Targeted and immunotherapy gaining market share, eroding dominant share of conventional chemotherapy.

• Cancer vaccines to see a compound annual growth rate of over 27% through 2019 (Infiniti Research).

The global oncology drugs market is expected to reach

US$119.3 billion by 2020, growing at a CAGR of

approximately 7% between 2015 and 2020.

Shifting of key drivers of growth in the global oncology

drugs market from 2014 (grey) to 2020 (red).

US$ billions

87.693.2

99.1105.4

112.2119.3

126.9135

143.7

2015 2016 2017 2018 2019 2020 2021 2022 2023

Surge of Biologics and

Targeted Therapies

High drug development costs

coupled with risk of failure

Adverse effects of

chemotherapy

Collaborations and

AcquisitionsFast Track Designations

Approvals and Clinical Trials

Increasing Investment

from Government, Public

and Private Sectors

Rising disposable incomes

and consumer healthcare

expenditures


IMMUNO-ONCOLOGY REVOLUTION

Conventional Chemotherapy

(1950s – present)

Targeted drug therapies

(late 1990s – present)

Immunotherapies

(Revolution happening now)

• Cancure is developing two immunotherapy drug candidates and one targeted cancer drug candidate.

• Ideally positioned in the current immuno-oncology revolution – from cancer treatments to cancer cures.


IMMUNO-ONCOLOGY REVOLUTION

“This year marks a turning point in cancer, as long-sought efforts to unleash

the immune system against tumors are paying off.

That's what made Science's… Breakthrough of the Year. In celebrating

cancer immunotherapy… harnessing the immune system to battle tumors…

to transform biological insights into lifesaving drugs…”

Jennifer Couzin-Frankel, Staff Writer

Science Magazine, 20 Dec 2013


RECENT ONCOLOGY DEALS

BIOTECH PHARMA YEAR MODALITY INDICATION STAGE PRICE (US)

Jiangsu Hengrui Incyte 2015 Antibody Solid tumours Ph1 $25M Upfront (L)

$770M Milestones

Intrexon Merck 2015 CAR T-cell Immuno-

oncology

Discovery $115M Upfront (L)

$826M Milestones

Flexus BMS 2015 Small molecule Immuno-

oncology

Preclinical

discovery

$1.25B (TS)

$800M Upfront

Aurigene Curis 2015 Small molecule Melanoma,

NSCLC

Ph1/2 $30M Upfront (L)

$52M Milestones*

Aduro Biotech Novartis 2015 Small molecule Immuno-

oncology

Preclinical $200M Upfront (L)

$500M Milestones

Cellectis Pfizer 2014 CAR T-cell Immuno-

oncology


$185M Milestones*

Definiens Medimmune 2014 Biomarkers Immuno-

oncology

Discovery $150M (TS)

+ Milestones

Aduro Biotech J&J Janussen 2014 LADD vaccine Mesothelioma,

Prostate


+ Milestones

Oryzon Roche 2014 Small molecule Acute myeloid

leukemia

Ph1 $21M Upfront (L)

>$500M Milestones

* Per drug candidate; (L) = License; (TS) = Trade Sale


CANCURE PIPELINE

• Series A to fund the first 18 months of development; planned Series B to fund the next 18 months of clinical

trials for each lead product candidate to achieve maximal value uplift.

• CNC118 has completed a pilot Phase 1 human clinical trial. Series A will fund the manufacturing of CNC118 for

entry into a Phase 1/2 human clinical trial; Series B will fund that clinical trial.

• CNC225 and CNC332 have demonstrated efficacy in animal models. Series A will fund their formal preclinical

development for entry into Phase 1 human clinical trials; Series B will fund both clinical trials.


LEAD PRODUCT CANDIDATES


• Genvax cancer vaccines “train” natural immune T-cells to detect and eliminate

cancer cells.

• Generates many T-cell populations against various cancer cell targets, with

potential for immunological memory to prevent cancer recurrence.

• Being developed for the treatment of advanced-stage malignant melanoma.

• Off-the-shelf therapy due to high genetic compatibility with cancer patients.

• Designed for combination with immune checkpoint inhibitors such as Keytruda

and with other cancer drugs to increase patient response rates.

• CNC118 was well tolerated in a pilot, Ph1 human clinical trial with nine patients.

• As a single agent, CNC118 showed 44% clinical benefit.

• Proprietary manufacturing methods and broad patent coverage.

GENVAX VIDEO - http://cancure.com/therapies/genvax-cnc118/

GENVAX PROGRAM

LEAD CANDIDATE - CNC118

http://cancure.com/therapies/genvax-cnc118/


RECENT CANCER VACCINE DEALS

Year Biotech Pharma Vaccine Indication Stage Deal

2015Gritstone

Oncologyn/a Neoantigens Lung Preclinical

VC Funding

US$102M

(Versant Ventures)

2015 Bavarian Nordic BMS Prostvac Prostate Ph3

Licence

US$60M Upfront

US$915M Milestones

2015 Dendreon Valeant Provenge Prostate MarketAcquisition

US$495M

2015 Aduro n/a GVAX CRS-207 Pancreatic Ph2IPO

US$119M IPO

2015 Northwest Bio n/a DCVax-L Glioblastoma Ph3

VC Funding

US$65M

(Neil Woodford)

2014 CureVacBoehringer

IngelheimCV9202 Lung Preclinical

Licence

US$45M Upfront

US$556M Milestones

2013 Inovio Roche INO-5150 Prostate Preclinical

Licence

US$10M Upfront

US$412M Milestones

2011 BioVex Amgen T-Vec

Head & neck,

Breast, Colorectal,

Pancreatic

Ph3

Acquisition

US$425M Upfront

US$575M Milestones


• Galectins are proteins that block cancer-fighting immune cells. Galectin-1 is

secreted by cancer cells, and is highly expressed in metastatic tumours.

• CNC225 blocks the cancer-promoting activity of galectin-1, and also inhibits

the growth of blood vessels to the tumour.

• High potency analog of a clinically validated drug with minimal side-effects.

• Patent protected in major markets for use in cancer therapy.

• Encouraging efficacy in mouse models of colon and breast cancer.

• 100% survival of mice treated with triple combination of a Genvax-type

vaccine and CNC225 with an immune checkpoint inhibitor.

• Galectins are relatively unexploited drug targets.

GALECTIN VIDEO - http://cancure.com/therapies/galectin-cnc225/

GALECTIN PROGRAM


http://cancure.com/therapies/galectin-cnc225/


“ALL ABOUT” DRUG COMBINATIONS

“It will likely be all about combinations: immunotherapy combinations or

targeted combinations. We will also be figuring out the sequencing of those

combinations… Even now, we can begin qualifying and quantifying patients in

terms of complete responses [cures]…

… Because of the successes with immune checkpoint inhibitors [ICIs] in

cancer immunotherapy, many new agents and strategies, including

combination approaches, are being developed at a fast pace.”

F. Stephen Hodi, Jr., MD

Dana-Farber Cancer Institute

Associate Professor of Medicine

Harvard Medical School


TRIPLE COMBINATION THERAPY• In vivo demonstration of synergistic effects of combining a prototype Genvax vaccine (mouse) and

CNC225 with immune checkpoint inhibitor (ICI) in a mouse model of colon cancer. In this well

established model, survival to 60 days is considered an experimental cure.

• The triple combination cured all (100%) of the mice with colon cancer. In contrast, treatment with

ICI alone only cured 30% of the mice.

Mouse model of colon cancer

Days of survival

% S

urv

ivin

g m

ice

100% of the mice were cured with the triple combination.

30% of the mice were cured with ICI alone.

Triple: ICI + Prototype Genvax vaccine + CNC225

Prototype Genvax vaccine + CNC225

ICI alone

Control untreated


GLOBAL PIPELINE OF EXPERIMENTAL

DRUGS TARGETING GALECTINS

Program Company Stage Indications Modality

GCS-100La Jolla

PharmaceuticalsPh2

Renal disease,

CancerComplex polysaccharide

LJPC-1010La Jolla

PharmaceuticalsPreclinical

Non-alcoholic

steatohepatitisComplex polysaccharide

GR-MD-02 Galectin Therapeutics Ph1Liver Fibrosis,

MelanomaNovel carbohydrates

GM-CT-01 Galectin Therapeutics Ph1 Melanoma Novel carbohydrates

TD139 * Galecto Biotech / BMS Ph2 Pulmonary fibrosis Small molecule inhibitor

OTX008 ** Oncoethix Ph1 Advanced solid tumours Calixarene compound

Galectin-3C Mandalmed Preclinical Cancer Truncated galectin-3

MP-3546 MediaPharma Preclinical Cancer Bispecific antibody

* Subject of a US$444M option deal with Bristol Myers Squibb (BMS) in November 2014.

** Oncoethix was acquired by Merck in 2014 for US$110M upfront and $265M in milestones.


• CNC332 is a targeted anti-cancer agent.

• Vitamin E analog that selectively targets tumour cells’ mitochondria, the cellular

subcomponents that produce bioenergy.

• Mitochondria are critical for cell survival, and are therefore recognised as

potentially valuable drug targets for cancer therapy.

• CNC332 causes cancer cells to self-destruct by natural “apoptosis”, and has

demonstrated anti-cancer efficacy in mouse models.

• One case of compassionate use of Mitocans prototype CNC331 for treatment

of inoperable mesothelioma – oncologist reported “dramatic clinical response”.

• Request from US National Cancer Institute (NCI) to conduct studies at NCI.

• 2 patent families with coverage in major markets.

• Proprietary manufacturing methods will enhance market exclusivity.

MITOCANS VIDEO - http://cancure.com/therapies/mitocans-cnc332/

MITOCANS PROGRAM


http://cancure.com/therapies/mitocans-cnc332/


TARGETED DRUGS IN THE MIX

“Novel Doublet and Triplet Combo Studies Explode in Melanoma”

– OncLive, 16 Apr 2015

“… a range of novel combinations of immunotherapies and targeted agents,

including treatment triplets, will likely be part of the future paradigm of

melanoma therapy as drug discovery in the field continues at a rapid pace.”

Jeffrey S. Weber, MD PhD

Moffitt Cancer Center

US National Cancer Institute


GLOBAL PIPELINE OF EXPERIMENTAL

DRUGS TARGETING MITOCHONDRIA

Drug Company Stage Indications Mechanism Deals

CPI613Cornerstone

PharmaceuticalsPh2

Pancreas, AML, NSCLC,

Lymphoma, Colorectal

Inhibition of α-ketoglutarate

dehydrogenase

Chiesi purchase of

Cornerstone US$255M

BirionapantTetralogic

PharmaceuticalsPh2 OvCa, AML

Inhibitor of apoptosis proteins

(SMAC mimetic) Recent US$50M IPO

LCL161 Novartis Ph2Solid tumours

Myeloma

Inhibitor of apoptosis proteins

(SMAC mimetic)-

Me-344 Mei Pharma Ph1/2 NSCLC, OvCa CaCx Inhibitor of mTORC1 & 2 pathway-

MP-MUS Houston Methodist Preclinical -Monoamine oxidase, mtDNA

acetylation-

DCAAcademic,

no patentsPh2 GBM

Inhibition of Pyruvate

dehydrogenase kinase-

Obatoclax GeminX (Cephalon) Ph2 Lymphoma Inhibition of BCL-2Cephalon purchase of

GeminX US$225M

AT-406 Ascenta Therapeutics Ph1 AML Inhibition of apoptosis proteins -

GamitrinibWistar’s Cancer

CenterPreclinical - Inhibition of HSP90 -


BOARD & MANAGEMENT

CEO

Dr Ian Nisbet, PhD

30+ years of drug development,

business development and general

management experience in the

international biotechnology sector.

Scientific Advisor, Director

Prof Steven Ralph

Therapy inventor. 30+ years

experience in biosciences.

Internationally recognised expert in

cancer immunology.

Director

Sydney Evans, LLB BCom

Legal and accounting expertise.

Experienced in mergers and

acquisitions.

COO, Director

Craig Miles

20+ years business development and

funds management experience.

VP Business Development

Christopher Boyer, BS MBA

Specialist in the selling of

biotechnology, 20+ years

spanning discovery, development

& commercialisation.

Project Manager

Dr Andrew Coley, PhD

20+ years early stage

biotech development.

Cancer & immunology

research, project and IP

management.

VP Manufacturing & QC

Dr Stephen Goodall, PhD

30+ years biotechnology

development, manufacturing,

operations and senior

management.

Scientific Advisor

Prof Jiri Neuzil

Therapy inventor. World-

leading investigator of

mitochondrial biology.


VALUE REALISATION

1. License Drug CandidatesLarge biopharmaceutical companies

2. Initial Public OfferingConsider market conditions

3. Trade SaleSale of the whole Cancure business

Cancure is focused on building value to maximise deal potential at optimal timing of 3-5 years.


CONTACT DETAILS

Chief Operating Officer,

Director

Craig Miles

[email protected]

+61 (0) 408 778 797

PO Box 1177, Broadbeach,

Queensland, Australia 4218

disclaimer - cancure · 2015. 11. 5. · cv9202 lung preclinical licence us$45m upfront us$556m...

Documents